June 2019 - Volume 3 - Issue - Contributor Index

Author:
Pabinger, I.
Author:
Pabst, C.

A PROOF OF CONCEPT OF LSD1-INHIBITON IN A PHASE I/II PILOT TRIAL OF TCP AND ATRA IN REFRACTORY / RELAPSED AML PATIENTS NOT ELIGIBLE FOR INTENSIVE THERAPY: PS1033

Wass, M.; Schlenk, R. F.; Göthert, J.; More

HemaSphere. 3:466-467, June 2019.

Author:
Pabst, T.

GENETICS AND MODELING OF HUMAN ACUTE ERYTHROID LEUKEMIA: S113

Fagnan, A.; Piqué Borràs, Riera M.; Ignacimouttou, C.; More

HemaSphere. 3:8-9, June 2019.

Author:
Pacelli, C.
Author:
Pachón, J.

REDUCED INTENSITY CONDITIONING AND AVOIDING USE OF BROAD SPECTRUM ANTIBIOTHERAPY ACTIVE AGAINST GRAM-NEGATIVE BACTERIA MIGHT HAVE A CUMULATIVE IMPACT IN REDUCING INTESTINAL MICROBIOTA MISBALANCE: PF757

Espigado, I.; Rodriguez, N.; Labrador, G.; More

HemaSphere. 3:332-333, June 2019.

Author:
Pachter, J.
Author:
Paci, C.
Author:
Paciello, G.

SETD2 NON-GENOMIC LOSS OF FUNCTION IN ADVANCED SYSTEMIC MASTOCYTOSIS (SM): PATHOGENETIC AND THERAPEUTIC IMPLICATIONS: PS1437

Mancini, M.; Monaldi, C.; De Santis, S.; More

HemaSphere. 3:662-663, June 2019.

Author:
Paciello, M. L.
Author:
Pack, R.
Author:
Packham, G.
Author:
Paczkowska, E.
Author:
Padella, A.

A NEW CLASSIFICATION OF ACUTE MYELOID LEUKEMIA BASED ON INTEGRATED GENOMICS AND METABOLOMICS: PF197

Simonetti, G.; Padella, A.; Mengucci, C.; More

HemaSphere. 3:51, June 2019.

“3C-UP” A NEW ADULT PHILADELPHIA NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA SUBGROUP: NOVEL MOLECULAR MARKERS: PS928

Ferrari, A.; Vitali, S.; Robustelli, V.; More

HemaSphere. 3:418, June 2019.

ADULT TRIPLE NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA FUSION DETECTION: CHALLENGING AIM FOR PH- ALTERNATIVE THERAPIES: PS931

Ferrari, A.; Vitali, S.; Baldazzi, C.; More

HemaSphere. 3:419-420, June 2019.

A NEW BIOMARKER OF RESPONSE TO 5-AZACITIDINE THERAPY IN MDS AND AML PATIENTS: SIRPB1: PS997

Cerchione, C.; Guadagnuolo, V.; Papayannidis, C.; More

HemaSphere. 3:448-449, June 2019.

Author:
Padgeva, T.

INTERFERON-FREE ANTIVIRAL THERAPY IN THE TREATMENT OF RELAPSE HEPATITIS C VIRUS ASSOCIATED MARGINAL ZONE LYMPHOMA: PB2014

Lepkov, S.; Subortceva, I.; Tumian, G.; More

HemaSphere. 3:911, June 2019.

Author:
Padilla, I.
Author:
Padron, E.

IMPACT OF 1ST LINE TREATMENT ON OVERALL SURVIVAL IN 1.633 PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA - A MULTINATIONAL COLLABORATIVE EFFORT COORDINATED BY THE AGMT STUDY GROUP: S840

Pleyer, L.; Leisch, M.; Kouraklis, A.; More

HemaSphere. 3:374-375, June 2019.

Author:
Padua, R.-A.
Author:
Pagani, A.
Author:
Pagani, C.

ISAVUCONAZOLE IN HEMATOLOGICAL PATIENTS: FINAL RESULTS OF A REAL-LIFE MULTICENTER SEIFEM (SORVEGLIANZA EPIDEMIOLOGICA DELLE INFEZIONI NELLE EMOPATIE) STUDY: PS1267

Cattaneo, C.; Gramegna, D.; Busca, A.; More

HemaSphere. 3:580-581, June 2019.

Author:
Pagani, I. S.
Author:
Pagano, L.

ISAVUCONAZOLE IN HEMATOLOGICAL PATIENTS: FINAL RESULTS OF A REAL-LIFE MULTICENTER SEIFEM (SORVEGLIANZA EPIDEMIOLOGICA DELLE INFEZIONI NELLE EMOPATIE) STUDY: PS1267

Cattaneo, C.; Gramegna, D.; Busca, A.; More

HemaSphere. 3:580-581, June 2019.

SETD2 NON-GENOMIC LOSS OF FUNCTION IN ADVANCED SYSTEMIC MASTOCYTOSIS (SM): PATHOGENETIC AND THERAPEUTIC IMPLICATIONS: PS1437

Mancini, M.; Monaldi, C.; De Santis, S.; More

HemaSphere. 3:662-663, June 2019.

A BAL-DRIVEN ANTIMICROBIAL TREATMENT IMPROVES CLINICAL OUTCOME IN HEMATOLOGIC MALIGNANCIES PATIENTS WITH LUNG INFILTRATES DETECTION: A PROSPECTIVE MULTICENTER STUDY OF THE SEIFEM GROUP: S1637

Marchesi, F.; Cattaneo, C.; Criscuolo, M.; More

HemaSphere. 3:756-757, June 2019.

Author:
Pagano, M. A.

TARGETED ACTIVATION OF THE PROTEIN PHOSPHATASES SHP-1 AND PP2A ABROGATES CONSTITUTIVE ACTIVATION OF SURVIVAL PATHWAYS IN LARGE GRANULAR LYMPHOCYTE LEUKEMIA (LGLL): PS1145

Pagano, M. A.; Tibaldi, E.; Brunati, A. M.; More

HemaSphere. 3:518-519, June 2019.

Author:
Page, C.
Author:
Pagel, J. M.

PROGNOSTIC TESTING AND TREATMENT APPROACHES BASED ON REAL-WORLD CLINICAL EXPERIENCE FROM AN INTERIM ANALYSIS OF THE INFORMCLL REGISTRY OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: PF383

Mato, A. R.; Barrientos, J. C.; Brander, D.; More

HemaSphere. 3:143-144, June 2019.

KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN ADULT PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA: END OF PHASE 1 RESULTS OF ZUMA-3: PS945

Shah, B. D.; Bishop, M. R.; Oluwole, O. O.; More

HemaSphere. 3:426, June 2019.

ANTITUMOR ACTIVITY OF PEMBROLIZUMAB PLUS DINACICLIB IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA: THE PHASE 1B KEYNOTE-155 STUDY: PS1075

Gregory, G.; Walker, P.; Mahadevan, D.; More

HemaSphere. 3:487, June 2019.

PRELIMINARY RESULTS OF A PHASE 1B/2 DOSE-ESCALATION AND COHORT-EXPANSION STUDY OF THE NONCOVALENT, REVERSIBLE BRUTON'S TYROSINE KINASE INHIBITOR (BTKI), VECABRUTINIB, IN B-CELL MALIGNANCIES: PS1148

Allan, J. N.; Patel, K.; Mato, A. R.; More

HemaSphere. 3:520, June 2019.

Author:
Pagliardini, T.

CHECKPOINT INHIBITOR TREATMENT BEFORE HAPLOIDENTICAL TRANSPLATATION IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA (HL) PATIENTS IS ASSOCIATED WITH HIGHER PFS WITHOUT INCREASED TOXICITIES: PS1241

De Philippis, C.; Legrande, F.; Bramanti, S.; More

HemaSphere. 3:565-566, June 2019.

GRAFT SOURCE AND PRE-TRANSPLANT DISEASE STATUS ARE THE MAIN VARIABLES AFFECTING THE OUTCOME OF T CELL-REPLETE HAPLOIDENTICAL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR HODGKIN LYMPHOMA: PS1246

Mariotti, J.; Devillier, R.; Bramanti, S.; More

HemaSphere. 3:568, June 2019.

Author:
Pagliaro, L.

TARGETING ONCOGENIC NOTCH1 IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH A NEW SELECTIVE SERCA INHIBITOR CAD204520: PF158

Marchesini, M.; Gherli, A.; Winter, A.-M. Lund; More

HemaSphere. 3:31, June 2019.

Author:
Pahl, H. L.
Author:
PAILLASSA, J.

REAL-WORLD RESULTS ON CD19 CAR T-CELL FOR 60 FRENCH PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA INCLUDED IN A TEMPORARY AUTHORIZATION FOR USE (ATU) PROGRAM: S1600

Thieblemont, C.; Legouill, S.; Di Blasi, R.; More

HemaSphere. 3:736-737, June 2019.

Author:
Paina, O.

INVASIVE YEAST INFECTIONS IN HEMATOLOGICAL PATIENTS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: PS1286

Popova, M.; Rogacheva, Y.; Volkova, A.; More

HemaSphere. 3:588-589, June 2019.

Author:
Paíno, T.

DISSECTING THE BONE MARROW IMMUNE MICROENVIRONMENT IN THE COMPLETE SPECTRUM OF MONOCLONAL GAMMOPATHIES: POTENTIAL IMPLICATIONS IN DISEASE PATHOGENESIS: PS1352

Puig, N.; Paíno, T.; Pérez, J. J.; More

HemaSphere. 3:617-618, June 2019.

Author:
Paiva, A.

GENOMIC CHARACTERIZATION OF CHRONIC LYMPHOCYTIC LEUKEMIA AND MULTIPLE MYELOMA: ROLE OF ARRAY COMPARATIVE GENOMIC HYBRIDIZATION (ACGH): PB1885

Nascimento, T.; Adão, D.; Oliveira, A.; More

HemaSphere. 3:858-859, June 2019.

Author:
Paiva, B.

SINGLE-CELL CHARACTERIZATION OF THE MULTIPLE MYELOMA (MM) IMMUNE MICROENVIRONMENT IDENTIFIES CD27- T CELLS AS POTENTIAL SOURCE OF TUMOR-REACTIVE LYMPHOCYTES: S121

Botta, C.; Perez, C.; Puig, N.; More

HemaSphere. 3:12-13, June 2019.

ROLE OF MEASURABLE RESIDUAL DISEASE (MRD) IN REDEFINING COMPLETE RESPONSE (CR) IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM THE PETHEMA-FLUGAZA PHASE III CLINICAL TRIAL: PF216

Paiva, B.; Martínez-Cuadrón, D.; Bergua, J. M.; More

HemaSphere. 3:59, June 2019.

CHROMATIN ACTIVATION AS A UNIFYING PRINCIPLE UNDERLYING PATHOGENIC MECHANISMS IN MULTIPLE MYELOMA: PF567

Ordoñez, R.; Kulis, M.; Russiñol, N.; More

HemaSphere. 3:236, June 2019.

HEAVY&LIGHT CHAIN MONITORING IN HIGH RISK SMOLDERING MULTIPLE MYELOMA PATIENTS INCLUDED IN THE GEM-CESAR TRIAL: COMPARISON WITH CONVENTIONAL AND MINIMAL RESIDUAL DISEASE IMWG RESPONSE ASSESSMENT: PF609

Puig, N.; Contreras, T.; Paiva, B.; More

HemaSphere. 3:258, June 2019.

CURATIVE STRATEGY (GEM-CESAR) FOR HIGH-RISK SMOLDERING MYELOMA: CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE (KRD) AS INDUCTION FOLLOWED BY HDT-ASCT, CONSOLIDATION WITH KRD AND MAINTENANCE WITH RD: S871

Mateos, M.-V.; Martínez-López, J.; Rodríguez-Otero, P.; More

HemaSphere. 3:390, June 2019.

DETAILED PHENOTYPIC, MOLECULAR AND FUNCTIONAL PROFILING OF MYELOID DERIVED SUPPRESSOR CELLS (MDSCS) IN THE TUMOR IMMUNE MICRO-ENVIRONMENT (TIME) OF MULTIPLE MYELOMA (MM): PS1348

Pérez, C.; Botta, C.; Zabaleta, A.; More

HemaSphere. 3:615-616, June 2019.

CRITICAL ANALYSIS OF THE STRINGENT COMPLETE RESPONSE IN MULTIPLE MYELOMA. AN UPDATED OF THE ANALYSIS BASED ON THE PETHEMA/GEM2012MENOS65 PHASE III CLINICAL TRIAL: PS1351

Ubieto, Jiménez A.; Martinez-Lopez, J.; Paiva, B.; More

HemaSphere. 3:617, June 2019.

DISSECTING THE BONE MARROW IMMUNE MICROENVIRONMENT IN THE COMPLETE SPECTRUM OF MONOCLONAL GAMMOPATHIES: POTENTIAL IMPLICATIONS IN DISEASE PATHOGENESIS: PS1352

Puig, N.; Paíno, T.; Pérez, J. J.; More

HemaSphere. 3:617-618, June 2019.

Author:
Pajic, T.
Author:
Pakdaman, S.

PRECLINICAL EVALUATION OF THE PRESERVATION OF RED BLOOD CELL CONCENTRATES IN HYPOXIA BY HYPOXIC STORAGE TECHNOLOGY FOR TRANSFUSION IN SICKLE CELL DISEASE.: S906

Bencheikh, L.; Nguyen, K.-A.; Chadebech, P.; More

HemaSphere. 3:409, June 2019.

Author:
Pal, D.
Author:
Pal, K.

MULTICENTRE STANDARDIZATION OF MINIMAL RESIDUAL DISEASE DETECTION AND QUANTITATION USING THE EUROCLONALITY-NGS ASSAY: PF175

Svaton, M.; Fronkova, E.; Kotrova, M.; More

HemaSphere. 3:39-40, June 2019.

Author:
Pala, C.
Author:
Palacio, C.

RESULTS OBTAINED FROM CLINICAL TRIALS PHASE I/II IN HEMATOLOGICAL MALIGNANCIES. CLINICAL EXPERIENCE OF A SINGLE CENTER: HOSPITAL 12 OCTUBRE.: PB1981

Pérez-Ávila, Cuéllar C.; Fernández, Alonso R.; Díaz, Ayala R.; More

HemaSphere. 3:899, June 2019.

SAFETY AND EFFECTIVENESS OF CHLORAMBUCIL-OBINUTUZUMAB IN THE FRONT LINE TREATMENT OF UNFIT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: REAL-LIFE DATA FROM ANDALUSIAN LYMPHOID NEOPLASM GROUP (GRANEL): PB1898

Puerta, Puerta J.M.; Palanco, Martín V.; Badiola, J.; More

HemaSphere. 3:865, June 2019.

Author:
Palandri, F.

OUTCOME OF PATIENTS WITH MYELOFIBROSIS AFTER RUXOLITINIB DISCONTINUATION: ROLE OF DISEASE STATUS AND TREATMENT STRATEGIES IN 218 PATIENTS: PF674

Palandri, F.; Breccia, M.; Bonifacio, M.; More

HemaSphere. 3:290, June 2019.

ELTROMBOPAG AS SECOND LINE THERAPY IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN ATTEMPT TO TREATMENT-FREE REMISSION. UPDATED RESULTS OF A PHASE II PROSPECTIVE STUDY BY GIMEMA GROUP: PF695

Lucchini, E.; Palandri, F.; Volpetti, S.; More

HemaSphere. 3:302, June 2019.

RISK FACTORS AND OUTCOME OF ACUTE MYELOID LEUKEMIA SECONDARY TO POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN ANALYSIS OF THE MYSEC COHORT: PS1458

Mora, B.; Guglielmelli, P.; Rumi, E.; More

HemaSphere. 3:671, June 2019.

IMPACT OF CYTOREDUCTIVE DRUGS ON SECOND CANCER IN MYELOPROLIFERATIVE NEOPLASMS: PS1468

Barbui, T.; Ghirardi, A.; Masciulli, A.; More

HemaSphere. 3:667-668, June 2019.

INCOMPLETE COUNT RECOVERY IN PATIENTS WITH COMPLETE REMISSION PRIOR TO ALLOGENEIC HCT FOR AML IS ASSOCIATED WITH A HIGH NON-RELAPSE MORTALITY WITHOUT AN INCREASED RELAPSE RISK: S1626

Innes, A.; Wooley, P.; Szydlo, R.; More

HemaSphere. 3:751-752, June 2019.

HIGH PLASMA CELL PROLIFERATIVE INDEX IS ASSOCIATED WITH A DOMINANT EXPANSION OF A SINGLE IMMUNOPHENOTYPIC SUBCLONE AND PREDICTS RESPONSE TO LENALIDOMIDE/DEXAMETHASONE IN RELAPSED MULTIPLE MIELOMA: PB2096

Arranz, E.; Palao, Sarmiento H.; Rodriguez, Díaz V.; More

HemaSphere. 3:944, June 2019.

Author:
Palazzi, G.
Author:
Palazzo, G.

CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: THE REAL LIFE EXPERIENCE OF RETE EMATOLOGICA PUGLIESE (REP): PF644

Mele, A.; Prete, E.; De Risi, C.; More

HemaSphere. 3:275-276, June 2019.

REAL-WORLD ITALIAN EXPERIENCE OF POMALIDOMIDE IN RELAPSED-REFRACTORY MYELOMA: RETROSPECTIVE MULTICENTER STUDY BY THE RETE EMATOLOGICA PUGLIESE AND BASILICATA: PB2130

Mele, G.; Pastore, D.; Di Renzo, N.; More

HemaSphere. 3:959, June 2019.

Author:
Palermo, F.
Author:
Paleta, A.

ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IMPROVES SURVIVAL IN AML PATIENTS WITH HIGH FLT3-ITD ALLELIC RATIO: PB1750

Papalexandri, A.; Kika, F.; Varelas, C.; More

HemaSphere. 3:804-805, June 2019.

Author:
Paliogianni, F.
Author:
Palladini, G.
Author:
Pallaud, C.

PROGNOSTIC AND PREDICTIVE IMPACT OF NPM1/FLT3-ITD GENOTYPES AS DEFINED BY 2017 EUROPEAN LEUKEMIANET RISK CATEGORIZATION FROM AML PATIENTS TREATED WITHIN THE INTERNATIONAL RATIFY STUDY: PF260

Döhner, K.; Thiede, C.; Jahn, N.; More

HemaSphere. 3:81-82, June 2019.

GENETIC LANDSCAPE OF FLT3-MUTATED ACUTE MYELOID LEUKEMIA (AML) PATIENTS TREATED WITHIN THE RATIFY TRIAL: CALGB 10603 (ALLIANCE): PS968

Jahn, N.; Panina, E.; Bullinger, L.; More

HemaSphere. 3:436, June 2019.

Show: